Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%. So, what information came out resulting in this massive single-day rise? What potential do Wall Street analysts see in this stock, and can the appreciation continue? I’ll break all that down and provide my perspective on this small company that just saw its value explode.
